Efficacy of PD-1 blockade in tumors with MMR deficiency

Immunotherapy. 2016;8(1):1-3. doi: 10.2217/imt.15.97. Epub 2015 Dec 8.

Authors

Valerie Lee¹, Dung T Le¹

Affiliation

¹ Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, 1650 Orleans Street, Room 407, Baltimore, MD 21287, USA.

PMID: 26643016
DOI: 10.2217/imt.15.97

No abstract available

Keywords: immune checkpoint inhibition; microsatellite instability; mismatch repair deficiency.

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Base Pair Mismatch*
Brain Neoplasms
Colorectal Neoplasms
Humans
Immunotherapy*
Mutation Accumulation
Neoplasms* / genetics
Neoplasms* / immunology
Neoplasms* / metabolism
Neoplasms* / therapy
Neoplastic Syndromes, Hereditary
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Programmed Cell Death 1 Receptor / immunology*

Substances

Antibodies, Monoclonal
PDCD1 protein, human
Programmed Cell Death 1 Receptor

Supplementary concepts

Turcot syndrome